Modulation of the blood–brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

E. Marleen Kemper(Amsterdam University Medical Centers), Olaf van Tellingen(Dutch Cancer Society), Ingrid Thuis(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jos H. Beijnen(The Netherlands Cancer Institute), Willem Boogerd(The Netherlands Cancer Institute)
Cancer Treatment Reviews
May 12, 2004
10.1016/j.ctrv.2004.04.001
Cited by 177

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768